Remicade the main source of growth for Mitsubishi Tanabe
This article was originally published in Scrip
Continued strong Japanese growth for Remicade (infliximab, licensed from Johnson & Johnson) helped offset other negative factors at Mitsubishi Tanabe Pharma (MTP) in the first half to September 30th, although overall sales at the company still fell.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.